As CSL embarks on a restructuring drive to save more than $500 million annually over the next three years, the Australian company’s workforce reduction plans have reached one of its subsidiaries in ...

CSL shares have tumbled 35% in 2025, partly attributed to an underwhelming FY 2025 results release and plans to spin off its Seqirus segment. The company's fiscal year 2026 revenue and profit outlook ...

CSL shares are down roughly 40% since acquiring Vifor in August 2022, an iron deficiency and kidney disease business and the largest acquisition in its history. However, several other factors have ...

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring ...

CSL Ltd said on Tuesday the fees it pays people to donate blood plasma, the core ingredient of its treatments, were stabilising after COVID-19 movement restrictions forced the Australian biomedical ...

Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...